Updated Overall Survival (OS) Data from a Phase 3 Trial of Ipilimumab (Ipi) vs. Placebo in Men Post Chemotherapy

In a poster presentation at the recent European Society of Medical Oncologists (ESMO) there was a very interesting poster presented updating a phase 3 clinical trial (CA184-043) which evaluated the overall survival (OS) with radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. This trial did not meet its endpoint [...]

Can Chemotherapy (Docetaxel) Be Enhanced By Zoledronic Acid Pretreatment in Resistant Prostate Cancer Cells *

Docetaxel is the only globally approved first-line chemotherapy for the treatment of castrate resistant prostate cancer. Yhe universal truth is that all men taking docetaxel will become refractory to the treatment. Zoledronic acid (ZA) is the most commonly used member of nitrogen-containing bisphosphonate family. By itself it has anti-tumor activity, including in prostate cancer. In [...]

Enhancement of Chemotherapy by Pretreating Cells with Zoledronic Acid (Zometa)*

Chemotherapy using docetaxel remains an important  therapy, despite the newly approved drugs, to treat hormone refractory prostate cancer. Chemotherapy improves survival, however, all men taking it will eventually become refractory to the treatment. Zoledronic acid (ZA) is the most potent member of nitrogen-containing bisphosphonate family and has anti-tumor activity in prostate cancer. In a study, [...]

Taxane-Based Chemotherapy Drugs May Be Underestimated, Especially Against Advanced Prostate Cancer

According to researchers at Weill Cornell Medical College in the Sept. 15 issue of the journal Cancer Research, taxne-based chemotherapy drugs are not well understood as they may be more powerful than many have believed. Generally, it is believed that taxane chemotherapy (paclitaxel, docetaxel and cabazitaxel) just stop a cancer cell from dividing -- but [...]

An Official Release of the Exciting Results of the Abiraterone Acetate (Zytiga) Trial

Today’s big news is about a media release made yesterday by Centocor Ortho Biotech with the official and final results of the Phase III clinical trial of abiraterone acetate (Zytiga™) plus prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already received at least one course of a docetaxel based [...]

An NCI Clinical Trail After Chemotherapy Has Failed

What do advanced prostate cancer survivors do once we fail chemotherapy? At this time there are no FDA approved next steps other than to take some time off and pray that restarting chemotherapy will again help us. To put in another way, we wait to die. There is a huge need to find additional strategies [...]